Looming obesity drug rivalry not a concern for Novo CEO

The demand for obesity drugs like Novo Nordisk’s Wegovy is so great that the company isn’t too worried about the entrance of rival drugs, Novo Nordisk CEO Lars Jorgensen said on Tuesday.